Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
mometasone furoate combination MDI 200 · 1 trial · 1 indication
AEs that are considered Related, Severe, and Serious, as determined by the investigator and using specific criteria defined in the protocol, are included in the primary results.
| Arm | Type | Description |
|---|---|---|
| MF/F 200/10 mcg BID | EXPERIMENTAL | - |
| MF/F 400/10 mcg BID | EXPERIMENTAL | - |
| F/SC 250/50 mcg BID | ACTIVE_COMPARATOR | - |
| F/SC 500/50 mcg BID | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| mometasone furoate combination MDI 200/10 mcg BID | DRUG | MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year |
| mometasone furoate combination MDI 400/10 mcg BID | DRUG | MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year |
| Fluticasone/Salmeterol 250/50 mcg BID | DRUG | F/SC 250/50 twice daily for 1 year |
| Fluticasone/Salmeterol 500/50 mcg BID | DRUG | F/SC 500/50 twice daily for 1 year |
Inclusion Criteria: * Subjects of either sex and any race, at least 12 years of age, with a diagnosis of asthma of at least 12 months. * Use of medium or high daily dose of ICS (alone or in combination with long-acting beta-agonist \[LABA\]) for at least 12 weeks prior to Screening and have been on...
Mometasone furoate combination MDI 200 is an investigational small molecule being developed for the treatment of asthma. It is a metered-dose inhaler formulation that combines mometasone furoate with formoterol. The drug is intended for patients with persistent asthma who have previously been treated with inhaled glucocorticosteroids.
Mometasone furoate combination MDI 200 is being developed by Organon & Co., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol OGN. Organon is conducting clinical development of this combination inhaler for the respiratory condition asthma.
Mometasone furoate combination MDI 200 is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 3 trial for this asthma treatment has been completed, with results expected to inform potential regulatory submissions.
Mometasone furoate combination MDI 200 has one completed Phase 3 clinical trial registered as NCT00379288. This study, titled 'Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)', enrolled 404 participants aged 12 years and older with asthma.
Yes, mometasone furoate combination MDI 200 is a combination product containing mometasone furoate and formoterol. The clinical trial NCT00379288 refers to it as the 'Mometasone Furoate/Formoterol Combination'. It is administered via a metered-dose inhaler (MDI) at a strength of 200 mcg.